APRI Score Calculator
Calculate the AST to Platelet Ratio Index (APRI) score to assess liver fibrosis and cirrhosis risk. Free online clinical tool with interpretation for significant fibrosis, severe fibrosis, and cirrhosis screening.
About This Calculator
The APRI score calculator (AST to Platelet Ratio Index) helps assess liver fibrosis and cirrhosis risk by combining two routine laboratory values: aspartate aminotransferase (AST) and platelet count. This non-invasive index was developed as an alternative to liver biopsy for identifying hepatic fibrosis in patients with chronic liver disease, particularly chronic hepatitis C (CHC). The calculator is intended for use by healthcare professionals and patients who have their lab results available.
The APRI formula is calculated as follows: APRI = [(AST level / AST upper limit of normal) / Platelet count] × 100. The AST upper limit of normal (typically 40 IU/L) standardizes the score across different laboratory reference ranges. For example, a patient with AST of 110 IU/L, AST ULN of 40 IU/L, and platelet count of 110 ×10⁹/L would have an APRI score of 2.5. Scores are interpreted using validated thresholds: ≥0.7 suggests significant fibrosis (F2+), ≥1.0 suggests severe fibrosis (F3) or cirrhosis (F4), and >1.5 has high predictive value for cirrhosis.
The APRI score was initially validated in patients with chronic hepatitis C but has since been studied in other chronic liver diseases including hepatitis B, non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease. The score's sensitivity and specificity vary by the cutoff used — the 0.7 threshold has 77% sensitivity and 72% specificity for significant fibrosis. The APRI is most useful at clinical extremes: low scores (<0.5) effectively rule out cirrhosis, while high scores (>1.5) effectively rule it in.
Several meta-analyses have confirmed the clinical utility of APRI as a cost-effective, widely available screening tool. It is particularly valuable in resource-limited settings where advanced imaging like FibroScan may not be accessible. The World Health Organization (WHO) recommends APRI as an alternative to liver biopsy for assessing liver fibrosis in hepatitis C patients before treatment initiation. However, midrange APRI values (0.5-1.5) should be interpreted with caution and may warrant further investigation with complementary tests such as FIB-4, FibroScan, or liver biopsy.
Regional Notes
India: Liver disease is a major health burden in India with high prevalence of hepatitis B, hepatitis C, NAFLD, and alcoholic liver disease. The APRI score is widely used in Indian hepatology practice as a cost-effective fibrosis screening tool. The Indian National Association for Study of the Liver (INASL) recommends APRI as part of the initial assessment for chronic liver disease. Laboratory reference ranges may vary between institutions.
United States: The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend APRI as a non-invasive alternative to liver biopsy for assessing fibrosis in hepatitis C patients. In the US, APRI is commonly used alongside FIB-4 in primary care and gastroenterology settings for initial liver fibrosis screening.
United Kingdom: NICE guidelines (NG50 and NG98) recommend APRI as a first-line non-invasive test for liver fibrosis assessment in primary care. In the UK, an APRI score below 0.5 is used to rule out advanced fibrosis in patients with abnormal liver function tests. The NHS Long Term Plan includes expanded use of non-invasive fibrosis tests including APRI.
Frequently Asked Questions
What is the APRI score?
The AST to Platelet Ratio Index (APRI) is a non-invasive biomarker used to predict hepatic fibrosis and cirrhosis in patients with chronic liver disease. It combines aspartate aminotransferase (AST) levels and platelet count into a single score. APRI was initially validated in chronic hepatitis C patients but is now used for various fibrotic liver diseases as an alternative to liver biopsy.
How is the APRI score calculated?
The APRI score is calculated using the formula: APRI = [(AST level / AST upper limit of normal) / Platelet count] × 100. For example, a patient with AST of 110 IU/L, AST upper limit of 40 IU/L, and platelet count of 110 ×10⁹/L would have an APRI of [(110/40)/110] × 100 = 2.5, indicating a high likelihood of cirrhosis.
What are the APRI score thresholds for fibrosis and cirrhosis?
APRI score interpretation uses the following thresholds: Significant fibrosis (F2 or higher) is indicated by an APRI ≥ 0.7 (77% sensitive, 72% specific). Severe fibrosis (F3) is indicated by APRI ≥ 1.0 (61% sensitive, 64% specific). Cirrhosis (F4) is indicated by APRI ≥ 1.0 (76% sensitive, 72% specific). Scores below 0.5 have high negative predictive value for ruling out cirrhosis, while scores above 1.5 have high positive predictive value for ruling in cirrhosis.
What does a low APRI score mean?
A low APRI score (less than 0.5) is associated with a high negative predictive value, meaning it can reliably rule out cirrhosis. However, midrange APRI values (0.5 to 1.5) are less definitive and may require additional testing. Patients with chronic liver disease and low APRI scores should still have regular monitoring as the score can change with disease progression.
What does a high APRI score above 1.5 mean?
An APRI score greater than 1.5 has a high positive predictive value for cirrhosis. This patient likely has significant hepatic fibrosis or cirrhosis requiring further evaluation with FibroScan, imaging studies, or liver biopsy for definitive staging. The patient should be referred to a hepatologist for comprehensive management including screening for portal hypertension and hepatocellular carcinoma.
Is APRI used in India, the US, and the UK?
Yes, the APRI score is used worldwide including India, the United States, and the United Kingdom as a non-invasive screening tool for liver fibrosis. In the US, AASLD guidelines recommend APRI as an alternative to liver biopsy for hepatitis C assessment. In India, APRI is widely used given the high prevalence of hepatitis B, hepatitis C, and NAFLD. In the UK, NICE guidelines recommend APRI as a first-line test for liver fibrosis in primary care settings. Unit standardization across all three countries uses IU/L for AST and ×10⁹/L for platelet count.
What other tests complement the APRI score?
Alongside APRI, clinicians commonly use the FIB-4 index, AST/ALT ratio, FibroScan (transient elastography), and NAFLD fibrosis score for comprehensive liver fibrosis assessment. Blood tests including bilirubin, albumin, INR, and complete blood count provide additional context. For viral hepatitis, HBsAg and anti-HCV testing are essential. Liver biopsy remains the gold standard when non-invasive tests are inconclusive.
Can the APRI score replace a liver biopsy?
The APRI score is a useful screening tool but cannot completely replace liver biopsy in all cases. APRI has good sensitivity and specificity for detecting significant fibrosis and cirrhosis, but midrange values (0.5 to 1.5) may be inconclusive. The score is most reliable at the extremes: below 0.5 (rules out cirrhosis) and above 1.5 (rules in cirrhosis). Liver biopsy or FibroScan may still be needed for definitive staging, especially in patients with indeterminate scores.